Changes to country-specific hepatitis A travel vaccination recommendation for UK travellers in 2017—responding to a vaccine shortage in the national context

• Published in: Public health (London) 2019-03, Vol.168, p.150-156
• Main Authors: Petersen, J., Freedman, J., Ford, L., Gawthrop, M., Simons, H., Edelstein, M., Plunkett, J., Balogun, K., Mandal, S., Patel, D.
• Format: Article
• Language: English
• Subjects: Changes; Children; Classification; Combined vaccines; Data processing; Friendship; General practice; Health services; Healthcare system; Hepatitis; Hepatitis A; High risk; Homosexuality; Immunization; Income; Men; Outbreaks; Prescribing; Prescription drugs; Public health; Risk; Rural areas; Rural communities; Sanitation; Serology; Shortages; Tourism; Travel; Travellers; Vaccination; Vaccines; Viral hepatitis infection
• ISSN: 0033-3506; 1476-5616
• DOI: 10.1016/j.puhe.2018.09.017

A routine review of hepatitis A travel vaccination recommendations was brought forward in June 2017 due to hepatitis A vaccine shortages and a concurrent outbreak in men who have sex with men (MSM). There were three objectives: first, to document the review process for changing the recommendations for the UK travellers in June 2017. Second, to study the impact of these changes on prescribing in general practice in 2017 compared with the previous 5 years. Third, to study any changes in hepatitis A notifications in June–October 2017 compared with the previous 5 years. This is an observational study. Travel vaccination recommendations for countries with either low-risk (90%) status according to child hepatitis A seroprevalence were not changed. A total of 67 intermediate-risk countries with existing recommendations for most travellers and with new data on rural sanitation levels were shortlisted for the analysis. Data on child hepatitis A seroprevalence, country income status, access to sanitation in rural areas and traveller volumes were obtained. Information about the vaccine supply was obtained from Public Health England. Changes to the existing classification were made through expert consensus, based on countries' hepatitis A seroprevalence, sanitation levels, level of income, volume of travel and hepatitis A traveller cases. Data on the number of combined and monovalent hepatitis A–containing vaccines prescribed in England, 2012–2017, were obtained from the National Health Service Business Service Authorities. The number of monthly prescriptions for January–September 2017 was compared with the mean number of prescriptions for the same month in the previous 5 years (t-test, α = 5%, df = 4). The number of hepatitis A cases notified in June–October 2017 not related to the MSM outbreak was compared with the number of notifications in the same months in previous years. A total of 36 countries were downgraded based on good access (80+% of population) to sanitation in rural areas and the intermediate-risk status in terms of child hepatitis A seroprevalence. For these countries, vaccination would only be recommended to travellers staying long term, visiting friends and relatives or staying in areas without good sanitation. There was a significant decline in hepatitis A vaccine prescriptions in June–September 2017, and there was no increase in the number of notifications. Hepatitis A vaccination recommendations for travel were revised in 2017